AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth Care
Peripheral Blood Stem Cell TransplantationTransplantation, AutologousHematopoietic Stem Cell TransplantationHematopoietic Stem Cell MobilizationTransplantation, HomologousLeukapheresisGranulocyte Colony-Stimulating FactorTransplantation ConditioningBone Marrow TransplantationStem CellsBlood Component RemovalHematopoietic Stem CellsAntigens, CD34MelphalanStem Cell TransplantationHematologic NeoplasmsMultiple MyelomaGraft vs Host DiseaseCombined Modality TherapyGraft SurvivalCyclophosphamideAntineoplastic Combined Chemotherapy ProtocolsTreatment OutcomeBusulfanLymphoma, Non-HodgkinEtoposideRecurrenceCord Blood Stem Cell TransplantationBlood Cell CountTissue DonorsMyeloablative AgonistsRemission InductionBone Marrow PurgingBlood CellsAntineoplastic Agents, AlkylatingLiver TransplantationSalvage TherapyWhole-Body IrradiationHematopoiesisTransplantation ChimeraDisease-Free SurvivalCarmustineThiotepaCytarabineRetrospective StudiesHodgkin DiseaseImmunosuppressive AgentsSurvival RateHistocompatibilitySurvival AnalysisTime FactorsBone MarrowVincristineHistocompatibility TestingCell SeparationLeukemiaTransplantation, IsogeneicKidney TransplantationImmunomagnetic SeparationIfosfamideBlood DonorsPlatelet CountLymphomaEmbryonic Stem CellsFeasibility StudiesBone Marrow CellsFlow CytometryColony-Forming Units AssayInfectionLeukemia, Myeloid, AcuteVidarabineCells, CulturedLeukocytes, MononuclearRecombinant ProteinsFollow-Up StudiesAdult Stem CellsCell TransplantationPOEMS SyndromeNeoplasm, ResidualCell DifferentiationDoxorubicinAntigens, CDGraft vs Tumor EffectImmunophenotypingTransplantation ImmunologyMyelodysplastic SyndromesLeukocyte CountBone Marrow DiseasesAnemia, AplasticNeoplasmsT-LymphocytesPlatelet TransfusionDexamethasoneProspective StudiesHeart TransplantationProchlorperazineIdarubicinAmyloidosisPluripotent Stem CellsLymphocyte Depletion
Multiple myelomaMarrowChemotherapy followed by autologousUmbilical cordMobilizationHigh-doseLymphomaHSCTTransplants2023LymphoproliferativeProgenitor cellsTumorLymphocytesSignificantlyHSCsRestoresAllogeneic hematopoieticAllogenicPediatricMyelomaHematopoietic stem cell mobiRemissionMalignantDifferentiationCytokinesSurvivalUnderwentPathologicMorbidity and mortaImmuneRecipientsClinicalOutcomesCardiacRituximabDonorCyclophosphamideTreatmentTransplant Cell Ther20211988CONCLUSIONSPatient'sTransfusionsPatientPhaseProspectiveRefractoryHarvestTherapyLymphomas
Multiple myeloma9
Marrow40
Chemotherapy followed by autologous2
Umbilical cord2
  • peripheral blood, or placental/umbilical cord blood). (cdc.gov)
  • and umbilical cord blood (PUCB), capable of 2017), associated with the results of the procedure restoring spinal cord function and immunology of and require a process of hospitalization and patients with indication for transplantation, with the prolonged hospital recovery. (bvsalud.org)
Mobilization5
High-dose7
Lymphoma17
  • Investigators will assess LP-284 as a treatment for those with B-cell non-Hodgkin lymphoma in a phase 1 trial. (cancernetwork.com)
  • OBJECTIVE: To assess the prognostic value of various parameters including positron emission tomography / computed tomography (PET/CT) and identify risk factors for survival of patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) treated with autologous stem cell transplantation (ASCT). (smw.ch)
  • Of the NHL patients, 59 (44%) had diffuse large B-cell lymphoma (DLBCL). (smw.ch)
  • Other risk factors for survival were primary refractory disease, initial lymphoma stage, number of previous chemotherapy lines, and high amounts of blood product transfusions. (smw.ch)
  • We conducted a nationwide, multicenter, prospective registry study for newly diagnosed patients with peripheral T-cell lymphoma (PTCL) to better define the clinical characteristics, treatment patterns, survival outcomes, and the role of upfront autologous stem cell transplantation (ASCT) in these patients. (e-crt.org)
  • This ulcerated nodule of localized primary cutaneous CD30+ anaplastic large cell lymphoma is relatively nonspecific in appearance. (medscape.com)
  • Although children, adolescents, and young adults with newly diagnosed B-cell non-Hodgkin's lymphoma enjoy excellent overall survival with current chemoimmunotherapy, those with relapsed and/or refractory disease have a dismal prognosis. (jnccn.org)
  • Children, adolescents, and young adults (CAYAs) with newly diagnosed B-cell non-Hodgkin's lymphoma (B-NHL) enjoy excellent overall survival (OS) with current frontline chemoimmunotherapy. (jnccn.org)
  • Kaplan-Meier curve showing probability of overall survival in children and adolescents with mature B-cell non‐Hodgkin's lymphoma with refractory or relapsed disease during or after therapy in the FAB/LMB96 international study. (jnccn.org)
  • Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: a report from the FAB/LMB 96 study group. (jnccn.org)
  • We present an unusual case of monomorphic T cell PTLD with features of angioimmunoblastic T cell lymphoma in an 8-year-old heart transplant patient, presenting with cranial nerve palsy. (karger.com)
  • Williams KM, Higman MA, Chen AR, Schwartz CL, Wharam M, Colombani P, Arceci RJ: Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma. (karger.com)
  • de Leval L, Gisselbrecht C, Gaulard P: Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. (karger.com)
  • Treatment recommendations for patients with diffuse large B-cell lymphoma (DLBCL) begin with evaluating the extent of the disease, performance status of the patient, and histologic subtypes. (medscape.com)
  • Chimeric antigen receptor T (CART) cell therapy targeting the B cell specific differentiation antigen CD19 has shown clinical efficacy in a subset of relapsed/refractory (r/r) diffuse large B cell lymphoma (DLBCL) patients. (frontiersin.org)
  • Diffuse large B cell lymphoma (DLBCL) represents the most frequent form of non-Hodgkin's lymphoma (NHL). (frontiersin.org)
  • This department provides medical care for patients with blood disorders, including anemia and thrombocytopenia, and neoplastic disorders such as leukemia and malignant lymphoma. (japanhospitalsearch.org)
HSCT10
  • There is a paucity of data examining the tolerance and outcome of hematopoietic stem cell transplantation (HSCT) for relapse after tositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • There is a paucity of data examining the tolerance andoutcome of hematopoietic stem cell transplantation (HSCT) for relapse aftertositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • Five patients received autologous HSCT: threemarrow and two peripheral blood stem cells. (cancernetwork.com)
  • 30,000 patients with blood-related malignancies receive HDC, which, if the response is satisfactory, could subsequently be followed by hematopoietic stem cell transplantation (HSCT). (bdbiosciences.com)
  • this is used in both autologous and allogenic HSCT. (bdbiosciences.com)
  • Opportunistic infections (OIs) are defined as any in- the infusion of hematopoietic stem cells from a donor fections that occur with increased frequency or severity into a patient who has received chemotherapy, which in HSCT patients. (cdc.gov)
  • There pediatric and adult autologous and allogeneic HSCT patients. (cdc.gov)
  • are basically 3 phases of immune recovery for HSCT patients, The purposes of the guidelines are (1) to summarize the beginning at day 0, the day of transplantation. (cdc.gov)
  • Hematopoietic stem cell transplantation (HSCT) affects serious risks for the patient, including death. (bvsalud.org)
  • Also, drastic changes in daily living habits, qualified and responsible for the implementation of changes in body image, long duration of treatment, HSCT since 2004, agreed to the Brazilian Unified periods of hospitalization and protective isolation, Health System, which meets the needs of the feeling of loss of control, fear of death and lack of patients with an indication for transplantation. (bvsalud.org)
Transplants3
  • In autologous stem cell transplants, the patient is their own stem cell donor. (leukaemia.org.au)
  • Autologous transplants are used to treat a number of different blood cancers. (leukaemia.org.au)
  • He has had 2 autologous stem cell transplants, 7 years and 1 year ago. (medscape.com)
20232
  • Part of Developmental Cell , p. 450-460, 2023. (uu.se)
  • Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase, Blood Advances, Vol.7, No.6, 1019-1032, 2023. (matci.jp)
Lymphoproliferative7
  • Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. (smw.ch)
  • PC-ALCL is one of the primary cutaneous CD30 + T-cell lymphoproliferative disorders, a wide spectrum of disease, with lymphomatoid papulosis (LyP) at the benign end of the spectrum and PC-ALCL at the malignant end. (medscape.com)
  • Blaes AH, Morrison VA: Post-transplant lymphoproliferative disorders following solid-organ transplantation. (karger.com)
  • Morovic A, Jaffe ES, Raffeld M, Schrager JA: Metachronous EBV-associated B-cell and T-cell posttransplant lymphoproliferative disorders in a heart transplant recipient. (karger.com)
  • Lundell R, Elenitoba-Johnson KS, Lim MS: T-cell posttransplant lymphoproliferative disorder occurring in a pediatric solid-organ transplant patient. (karger.com)
  • Draoua HY, Tsao L, Mancini DM, Addonizio LJ, Bhagat G, Alobeid B: T-cell post-transplantation lymphoproliferative disorders after cardiac transplantation: a single institutional experience. (karger.com)
  • Yang F, Li Y, Braylan R, Hunger SP, Yang LJ: Pediatric T-cell post-transplant lymphoproliferative disorder after solid organ transplantation. (karger.com)
Progenitor cells5
  • For many hematopoietic malignancies, collection and infusion of CD34+ hematopoietic stem/progenitor cells following chemotherapy is critical. (bdbiosciences.com)
  • The bone morrow contains several stem cell types including hematopoetic stem cells, endothelial progenitor cells, mesenchymal (stromal) stem cells and multipotent adult progenitor cells. (escardio.org)
  • Although there is no definitive evidence, combinations of progenitor cells seem to be more benefical than specific stem cell type for cardiac repair (3). (escardio.org)
  • Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia. (uchicago.edu)
  • This article contains highlights of "Guidelines for Pre- allogeneic or autologous, depending on the source of venting Opportunistic Infections among Hematopoi- the transplanted hematopoietic progenitor cells. (cdc.gov)
Tumor3
  • elicits antiproliferative and proapoptotic activities in vitro in solid and hematologic tumor cells. (medscape.com)
  • ALCL was recognized in 1985, when tumor cells consistently demonstrated labeling by the monoclonal antibody Ki-1, a marker later shown to recognize the CD30 antigen. (medscape.com)
  • The effect of potential reinfusion of tumor cells has not been well-studied. (fresenius-kabi.com)
Lymphocytes3
Significantly1
  • For the 20 OSMS patients, the overall EDSS score decreased significantly after transplantation (P = 0.016), while visual functions had no significant improvement (P = 0.716). (cellsurgicalnetwork.com)
HSCs2
Restores1
Allogeneic hematopoietic5
Allogenic2
  • This BMT unit is at par with the best in the world, and performs both Allogenic, and Autologous BMT's. (mediescapes.com)
  • Facilities for both autologous and Allogenic transplantation are available at the hospital, using a cell separator for stem cell harvest procedures and a freezing system to cryo-preserve the cells for future use. (mediescapes.com)
Pediatric2
  • Detection of Mucor velutinosus in a blood culture after autologous peripheral blood stem cell transplantation: a pediatric case report. (wikipedia.org)
  • T cell PTLD is rare, particularly in pediatric patients. (karger.com)
Myeloma6
  • We tested whether natural killer cells expanded by co-culture with K562 cells transfected with 41BBL and membrane-bound interleukin-15 could kill myeloma cells with a high-risk gene expression profile in vitro and in a unique model which recapitulates human myeloma. (haematologica.org)
  • These mice are devoid of endogenous natural killer and T-cell activity and were used to determine whether adoptively transferred expanded natural killer cells could inhibit myeloma growth and myeloma-associated bone destruction. (haematologica.org)
  • Results Natural killer cells from healthy donors and myeloma patients expanded a median of 804- and 351-fold, respectively, without significant T-cell expansion. (haematologica.org)
  • Expanded natural killer cells killed both allogeneic and autologous primary myeloma cells avidly via a perforin-mediated mechanism in which the activating receptor NKG2D, natural cytotoxicity receptors, and DNAX-accessory molecule-1 played a central role. (haematologica.org)
  • Adoptive transfer of expanded natural killer cells inhibited the growth of established OPM2 and high-risk primary myeloma tumors grown in the murine model. (haematologica.org)
  • The transferred, expanded natural killer cells proliferated in vivo in an interleukin-2 dose-dependent fashion, persisted up to 4 weeks, were readily detectable in the human bone, inhibited myeloma growth and protected bone from myeloma-induced osteolysis. (haematologica.org)
Hematopoietic stem cell mobi1
  • Hematopoietic stem cell mobilizer binds to the CXCR4 chemokine receptor and inhibits the binding of its ligand, stromal cell-derived factor-1-alpha (SDF-1-alpha). (drugs.com)
Remission4
Malignant1
  • Lesions are caused by bone replacement by expanding plasmacytomas or by cytokines that are secreted by malignant plasma cells that activate osteoclasts and suppress osteoblasts, leading to bone loss. (merckmanuals.com)
Differentiation4
  • Moreover, it seems that paracrine action of skeletal myoblasts facilitate neighboring cardiomyocytes to maintain their replicative potential and/or stimulate differentiation of native cardiac stem cells (8,9). (escardio.org)
  • It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. (uchicago.edu)
  • Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines. (uchicago.edu)
  • In the second part of our study, combining in-situ-hybridization and immunohistochemical methods, we were able to show that there is a migration of donor cells into the central nervous system of the recipient after peripheral blood stem cell transplantation as well as a differentiation of these cells into other cell types. (uni-goettingen.de)
Cytokines1
  • In vitro , CD3 + CD8 + CD27 - CD28 - compared to CD3 + CD8 + CD27 + CD28 + CART cells displayed similar CD19 + target cell-specific cytotoxicity, but were hypoproliferative and produced less cytotoxic cytokines (IFN-γ and TNF-α). (frontiersin.org)
Survival5
  • Cell therapy is a potential new treatment for post MI patients, but the main challenges are : the necessity to preserve immune competency and to gain adequate nutrition and homing signals necessary for stem cells' engraftment and survival. (escardio.org)
  • Repair of scar tissue constitutes a challenge for cardiac stem cell therapy due to lack of adequate nutrition and homing signals necessary for stem cells' engraftment and survival. (escardio.org)
  • Reversible proteasome inhibition disrupts pathways supporting cell growth, thus decreasing cancer cell survival. (medscape.com)
  • Although most clinicians would agree that hematopoietic progenitor cell transplantation after reinduction therapy is frontline therapy for these patients, there is no consensus as to what type of hematopoietic progenitor cell transplantation promises the best event-free and overall survival. (jnccn.org)
  • 1 Significant advances have been made by combining novel agents with autologous peripheral blood stem cell transplantation which allows for long-term disease-free survival in the majority of transplant-eligible patients. (haematologica.org)
Underwent3
Pathologic1
Morbidity and morta2
  • 1 Improvements in transplantation techniques, including the wider use of cell selection, have contributed to a significant reduction in the morbidity and mortality associated with conventional transplantation. (bdbiosciences.com)
  • Hopefully, following the recommendations made in the guidelines will reduce morbidity and mortality from opportunistic infections in hematopoietic stem cell transplant recipients. (cdc.gov)
Immune2
  • Various cell types have been tested experimentally for cardiac repair so far, but only those of autologous origin have yet undergone clinical testing due to immune competency. (escardio.org)
  • We investigated the safety and efficacy of immune suppression and autologous haemopoietic stem-cell infusion to treat such patients. (northwestern.edu)
Recipients3
  • Gassas A , Grant R , Richardson S , Dupuis LL , Doyle J , Allen U , Predictors of viridans streptococcal shock syndrome in bacteremic children with cancer and stem-cell transplant recipients. (cdc.gov)
  • Six patients relapsed, includingall five autologous and one allogeneic recipients. (cancernetwork.com)
  • Although previous recommendations for preventing transmission of human immunodeficiency virus (HIV) through transplantation of human tissue and organs have markedly reduced the risk for this type of transmission, a case of HIV transmission from a screened, antibody-negative donor to several recipients raised questions about the need for additional federal oversight of transplantation of organs and tissues. (cdc.gov)
Clinical7
  • Clinical outcome of autologous peripheral blood stem cell transplantation in opticospinal and conventional forms of secondary progressive multiple sclerosis in a Chinese population. (cellsurgicalnetwork.com)
  • To evaluate clinical outcomes of autologous peripheral blood stem cell transplantation (APBCST) between opticospinal multiple sclerosis (OSMS) and conventional multiple sclerosis (CMS) during disease progressive stage in a Chinese population. (cellsurgicalnetwork.com)
  • Preclinical and some small-scaled clinical trials have suggested feasibility and safety of cardiac stem cell therapy. (escardio.org)
  • Cell therapy is currently emerging as a potential new treatment for post MI patients with the assumption that recolonization of the areas of scarred myocardium with exogenously supplied surrogates or precursors of cardiomyocytes can restore function and ultimately affect clinical outcomes. (escardio.org)
  • Blood cell and serum markers, along with clinical data of DLBCL patients who were scheduled for CART cell therapy were evaluated to search for biomarkers predicting CART cell responsiveness. (frontiersin.org)
  • In clinical trials, stem cell transplantation reduced the CD activity index (SMD − 2.10, P = 0.000), the CD endoscopic index of severity (SMD − 3.40, P = 0.000) and simplified endoscopy score for CD (SMD − 1.71, P = 0.000) and improved the inflammatory bowel disease questionnaire score (SMD 1.33, P = 0.305) compared to control values. (biomedcentral.com)
  • abstract： PURPOSE:M30 and M65 ELISAs are proposed as surrogate biomarkers of tumour cell death in patients and are being applied increasingly in the pharmacodynamic (PD) evaluation of anticancer drugs during clinical trials. (shengsci.com)
Outcomes2
  • Monocyte subpopulation recovery as predictors of hematopoietic cell transplantation outcomes. (stembook.org)
  • HCT, whether it be autologous, allogeneic, or tandem, has been and continues to be an integral part of therapy, with varying outcomes as delineated in Table 2 . (jnccn.org)
Cardiac1
Rituximab1
  • Two courses of four weekly infusions of rituximab with or without interferon-2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas. (cancercentrum.se)
Donor5
Cyclophosphamide2
Treatment8
Transplant Cell Ther1
20211
19881
CONCLUSIONS1
  • Conclusions These studies provide the rationale for testing expanded natural killer cells in humans. (haematologica.org)
Patient's3
  • The choice of chemotherapy depends on several factors, including the patient's performance status, age, renal function, desire for inpatient or outpatient therapy, and likelihood of receiving future autologous stem cell transplantation. (medscape.com)
  • They are used to replace stem cells that have been damaged by high doses of chemotherapy , used to treat the patient's underlying disease. (leukaemia.org.au)
  • Staff attempted to draw blood for work-up before a CT evaluation of the patient's lungs, but had difficulty in obtaining a specimen that the laboratory would accept. (medscape.com)
Transfusions2
  • Red blood cell transfusions are given when your haemoglobin levels are too low. (leukaemia.org.au)
  • A type and antibody screen specimen obtained before the transfusions revealed that his red cells were type B positive, a screen for unexpected antibodies was negative, and direct antibody tests (DAT) for both anti-IgG and anti-C3b were also negative. (medscape.com)
Patient2
  • Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma. (shengsci.com)
  • As a result of persistent hypotension, the patient was transfused with 3 units of uncrossmatched, type O red blood cells. (medscape.com)
Phase3
  • Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for untreated non-squamous non-small-cell lung cancer. (shengsci.com)
  • abstract： PURPOSE:We conducted a phase II trial to evaluate the efficacy and safety of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for advanced non-squamous non-small-cell lung cancer (NSCLC). (shengsci.com)
  • Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399. (cdc.gov)
Prospective2
  • Exclusion of prospective blood donors based on their acknowledged risk behaviors for human immunodeficiency virus (HIV) infection began in 1983 (1). (cdc.gov)
  • In 1985, when tests for HIV antibody became available, screening prospective donors of blood, organs, and other tissues also began (2,3). (cdc.gov)
Refractory1
  • 1 - 3 However, those with relapsed and/or refractory (R/R) disease have had a historically dismal OS of ≤30% despite reinduction therapy and autologous hematopoietic progenitor cell transplantation (autoHCT) ( Figure 1 ). (jnccn.org)
Harvest2
  • 2 Evaluation of harvest adequacy requires the use of reliable progenitor cell assays and this is usually achieved by CD34 cell counting using flow cytometry. (bdbiosciences.com)
  • Facilities for Peripheral Stem Harvest are also available. (mediescapes.com)
Therapy9
  • The best response after surgery, HDCT, and radiation therapy was assessed 60 days after transplantation. (elsevierpure.com)
  • As such, stem cell therapy cannot be regarded as a valid therapeutic option for patients with cardiovascular disease in the present era of evidenced-based medicine, yet it holds great hope for the future. (escardio.org)
  • In elderly patients or patients in whom autologous transplantation is not possible in the future, melphalan and prednisone (MP) therapy is preferred because of its ease of administration and low toxicity. (medscape.com)
  • This review outlines the disparate types of stem cell therapy that have been used in this difficult-to-treat population as well as the role of maintenance and CAR T-cell therapy in conjunction with stem cell therapy. (jnccn.org)
  • and the role of CAR T-cell therapy as it relates to HCT as therapies for R/R B-NHL. (jnccn.org)
  • Despite this heterogeneous response, blood pre-infusion biomarkers predicting responsiveness to CART cell therapy are currently understudied. (frontiersin.org)
  • We explored whether stem cell therapy was effective for animal models and patients with Crohn's disease (CD). (biomedcentral.com)
  • Stem cell transplantation is a valuable supplementary therapy for CD. (biomedcentral.com)
  • Several studies have evaluated the safety and effectiveness of CD stem cell therapy, but the results remain controversial. (biomedcentral.com)
Lymphomas1
  • Anaplastic large cell lymphomas (ALCLs) are distinguished from other lymphomas by their anaplastic cytology and constant membrane expression of the CD30 antigen (an activation marker for B or T cells). (medscape.com)